iCAD, Inc. (ICAD)
NASDAQ: ICAD · Real-Time Price · USD
1.830
+0.060 (3.39%)
Dec 20, 2024, 4:00 PM EST - Market closed
iCAD, Inc. Revenue
iCAD, Inc. had revenue of $4.22M in the quarter ending September 30, 2024, with 3.54% growth. This brings the company's revenue in the last twelve months to $18.94M, up 10.03% year-over-year. In the year 2023, iCAD, Inc. had annual revenue of $17.32M, down -12.54%.
Revenue (ttm)
$18.94M
Revenue Growth
+10.03%
P/S Ratio
2.55
Revenue / Employee
$274,493
Employees
69
Market Cap
48.23M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 17.32M | -2.48M | -12.54% |
Dec 31, 2022 | 19.80M | -13.84M | -41.13% |
Dec 31, 2021 | 33.64M | 3.94M | 13.27% |
Dec 31, 2020 | 29.70M | -1.64M | -5.24% |
Dec 31, 2019 | 31.34M | 5.72M | 22.32% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Fortress Biotech | 81.50M |
Rapid Micro Biosystems | 26.17M |
Omega Therapeutics | 8.10M |
Nutriband | 2.02M |
vTv Therapeutics | 1.00M |
Exicure | 500.00K |
Inovio Pharmaceuticals | 203.41K |
ICAD News
- 10 days ago - SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations - GlobeNewsWire
- 17 days ago - CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024 - GlobeNewsWire
- 25 days ago - iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024 - GlobeNewsWire
- 5 weeks ago - iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - iCAD Reports Financial Results for Third Quarter Ended September 30, 2024 - GlobeNewsWire
- 6 weeks ago - iCAD to Attend 15th Annual Craig-Hallum Alpha Select Conference - GlobeNewsWire
- 2 months ago - iCAD to Participate in the LD Micro Main Event XVII - Newsfile Corp
- 2 months ago - iCAD Highlights Global Availability of ProFound Cloud and International Expansion Milestones at JFR 2024 - GlobeNewsWire